OCT anatomical outcomes for macula oedema, subretinal fluid and vitreomacular traction abnormality by treatment group

	All	Ranibizumab	Aflibercept	Bevacizumab
Macula Oedema				
Baseline				
null	7	3	1	3
no evidence	5 (1%)	2 (1%)	2 (1%)	1 (1%)
diffuse	19 (4%)	8 (5%)	8 (5%)	3 (2%)
cystic	90 (20%)	25 (16%)	33 (22%)	32 (21%)
mixed	342 (75%)	117 (77%)	110 (72%)	115 (76%)
Week 52				
null	53	21	13	19
no evidence	147 (36%)	56 (42%)	62 (44%)	29 (21%)
diffuse	64 (16%)	18 (13%)	24 (17%)	22 (16%)
cystic	103 (25%)	27 (20%)	35 (25%)	41 (30%)
mixed	96 (23%)	33 (25%)	20 (14%)	43 (32%)
Week 100				
null	67	22	24	21
no evidence	150(38%)	55(41%)	59 (45%)	36 (27%)
diffuse	55 (14%)	17 (13%)	19 (15%)	19 (14%)
cystic	87 (22%)	26 (20%)	29 (22%)	32 (24%)
mixed	104 (26%)	35 (26%)	23 (18%)	46 (35%)
Subretinal detachment				
Baseline				
null	26	9	8	9
no evidence	126 (29%)	39 (27%)	45 (31%)	42 (29%)
questionable	9 (2%)	6 (4%)	1 (1%)	2 (1%)
definite	196 (43%)	62 (41%)	63 (41%)	71 (48%)
Week 52				
null	55	22	13	20
no evidence	352(86%)	113 (85%)	124(88%)	115(86%)
questionable	0(0%)	0(0%)	0(0%)	0(0%)
definite	56(14%)	20(15%)	17(12%)	19(14%)
Week 100				
null	67	22	24	21
no evidence	342(86%)	118(89%)	111(85%)	113(85%)

questionable	0(0%)	0(0%)	0(0%)	0(0%)
definite	54(14%)	15(11%)	19(15%)	20(15%)
VItreomacular Interface Abnormality				
Baseline				
null	9	3	1	5
no evidence	250(55%)	87(57%)	88(58%)	75(50%)
questionable	8(2%)	3(2%)	2(1%)	3(2%)
definite	196(43%)	62(41%)	63(41%)	71(48%)
Week 52				
null	53	21	13	19
no evidence	221(54%)	73(54%)	76(54%)	72(53%)
questionable	4(1%)	0(0%)	3(2%)	1(1%)
definite	185(45%)	61(46%)	62(44%)	62(46%)
Week 100				
null	67	22	24	21
no evidence	219(55%)	74(56%)	77(59%)	68(51%)
questionable	9(2%)	4(3%)	4(3%)	1(1%)
definite	168(42%)	55(41%)	49(38%)	64(48%)

Null= not available due to patient withdrawal or image not taken or not saved. Ungradable= grader unable to grade due to poor image quality or feature(s) obscured e.g. by overlying macula oedema.